Predicting progression of common cancers

January 13, 2004

The idea that cancer cells go through a fateful transition that turns them into fast-growing, invasive, metastasizing tumors first surfaced in the early 1970s. By the mid-1980s histological analysis revealed a similarity between the tumor "microenvironment" and that of a healing wound, prompting Harvard pathologist Harold Dvorak to describe cancer as a wound that does not heal. With no systematic method to measure the "wound-like" features in cancer, however, scientists had no way to evaluate the risk that a wound-healing genetic program may pose in cancer progression.

In an effort to create a framework for evaluating the relationship between tumor and wounds, Howard Chang and his colleagues in Patrick Brown's lab at Stanford University examined the gene expression profile of fibroblasts responding to serum in cell culture--a process that shares certain features with wound healing. Fibroblasts are involved in wound healing, and serum is encountered in the body where blood leaks out of blood vessels (such as sites of injury), and is thought to be a major initiator of the wound-healing response.

Though fibroblasts from different sites in the body differ in their properties and gene expression profiles, Brown and colleagues found that they share a common expression pattern in response to serum. From this expression profile, Chang et al. identified a core group of genes--a genetic signature--associated with a serum response. Because many of the genes in the signature were known to be involved in various wound-healing processes--such as matrix remodeling, cell motility, and angiogenesis--Chang et al. used this signature as a surrogate marker to measure how much tumors may be like wounds. When they compared the wound-like genetic signature with the expression profiles of various clinical tumor samples, they found the signature was always present in certain cancers--prostate and liver cell carcinomas--and occurred variably in others--breast, lung, and gastric carcinomas. In each of these three latter types of tumors, patients with tumors carrying the serum-activated wound-like genetic signature had a significantly increased risk of metastasis and death compared to patients with tumors that lacked the signature.

These results reveal a similarity between the molecular programs in normal wound healing and tumor progression and metastasis and suggest that a wound-like phenotype is a general risk factor for metastasis and aggressive behavior in many of the most common cancers. And the serum-response expression signature provides a valuable new diagnostic tool for predicting tumor behavior and determining a patient's prognosis.
-end-
research article: http://www.plos.org/downloads/plbi-02-02-brown.pdf

related image: http://www.plos.org/downloads/plbi-02-02-brown.jpg

CONTACT:

Patrick O. Brown
Stanford University
Stanford, CA 94305-5307
United States of America
phone 650-736-0005
pbrown@cmgm.stanford.edu

Howard Chang
Stanford University
Stanford, CA 94305-5307
United States of America
650-725-7569
howchang@stanford.edu

PLOS

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.